Insulin Resistance Market - Forecast(2024 - 2030)

Insulin Resistance Market size is forecast to reach 38.19Bn by 2025, growing at a CAGR of 5.3% during the forecast period 2020-2025. Insulin resistance  is a pathological condition in which cells fail to respond normally to the hormone insulin. Increasing prevalence of diabetes and rise in sedentary lifestyle are the major factors driving the growth of the market. Increasing government initiative to increase insulin resistance is set to further enhance the overall market demand of insulin resistance during the forecast period 2020-2025. 

The report: “Insulin Resistance Market Forecast (2019-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Insulin Resistance Market. 

By Type: Rapid Acting Insulin, Long Acting Insulin, Short Acting Insulin, Intermediate Insulin and Ultra Acting Insulin.

By Drug Class:  Biguanides, Corticosteroids, Thiazolidinediones, Insulin, Lipase Inhibitors, Glucagon-like Peptide 1 (GLP-1) Receptor Agonists and Dipeptidyl Peptidase-4 (DPP-4).

By Drug: Branded and Generics

By Diseases: Diabetes, Pre-Diabetes, Metabolic Syndrome, Hypertension, Obesity, Dyslipidemia and Alzheimer’s Disease

By End Users: Home Healthcare, Hospitals, Over the counter, Clinics and Others 

By Geography: North America, Europe, Asia Pacific and RoW

The Rapid Acting Insulin   segment held the largest share in the Insulin Resistance Market   in 2019 and is estimated to grow at a CAGR of 3.22% during the forecast period 2020-2025 owing to its usage in insulin pumps to provide a continuous low level of insulin. This continuous flow of basal insulin is the ongoing insulin that is needed to manage normal fluctuations in blood sugar between meals and during sleep. Ultra‐long acting insulin is defined as insulin showing the clinically significant biological action of a glucose lowering effect beyond 24 hours after subcutaneous injection in individuals with diabetes mellitus. Rapid acting insulin is set to be the highest growing segment during the forecast period 2020-2025.

Diabetes segment held the largest share in the Insulin Resistance Market in 2019 and is estimated to grow at a CAGR of 3.29% during the forecast period 2020-2025. Diabetes is a condition that impairs the body’s ability to process blood glucose also known as blood sugar. Diabetes can lead to a buildup of sugars in the blood, which can increase the risk of dangerous complications, including stroke and heart disease. Different kinds of diabetes can occur and managing the condition depends on the type. Not all forms of diabetes stem from a person being overweight or leading an inactive lifestyle. Dyslipidemia refers to unhealthy levels of one or more kinds of lipid (fat) in your blood. Dyslipidemia is divided up into primary and secondary types. Primary dyslipidemia is inherited. Secondary dyslipidemia is an acquired condition. That means it develops from other causes, such as obesity or diabetes. Diabetes is set to be the fastest growing segment during the forecast period 2020-2025 boosting the growth of the Insulin Resistance Market.

Asia Pacific dominates the insulin resistance market with a share of more than 38%, followed by North America owing to the rising body mass index level and increase in smoking habits among population. Increasing cases of diabetes and other co-morbid disorders is increasing the growth of the insulin resistance market in the Asia Pacific region.

However, North America is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the high body mass index. Sedentary lifestyles rise in diabetes patients and increasing air population is boosting the growth of the insulin resistance market.

Rising healthcare providers and increasing incidence of diabetes is increasing the growth of the insulin resistance market. Insulin resistance  is a pathological condition in which cells fail to respond normally to the hormone insulin. Insulin is a hormone that allows glucose to enter cells which also reduces blood glucose (blood sugar). Insulin is released by the pancreas in response to carbohydrates consumed in the diet. In states of insulin resistance, the same amount of insulin does not have the same effect on glucose transport and blood sugar levels. Diabetes occurs when glucose levels become higher as the resistance increases and compensatory insulin secretion fails. Gestational diabetes is diabetes diagnosed for the first-time during pregnancy. Like other types of diabetes, gestational diabetes affects how your cells use sugar. Gestational diabetes causes high blood sugar that can affect pregnancy and baby's health. Thus, boosting the growth of the insulin resistance market.

Increasing prevalence of diabetes and rise in sedentary lifestyle is increasing the growth of the insulin resistance market. Rise in sedentary lifestyle with aging population  and increasing obesity prevalence is poised to give rise to patients suffering from insulin resistance.  Adoption of sedentary lifestyle due to and reduced physical activities are adding to worries. The glucose tolerance test  is a medical test in which  glucose is given and blood samples taken afterward to determine how quickly it is cleared from the blood. The test is usually used to test for diabetes, insulin resistance, impaired beta cell function  and sometimes reactive hypoglycemia and acromegaly or rarer disorders of carbohydrate metabolism. Thus, increasing the growth of the insulin resistance market.

Some of the factors that is set to impede the growth of the Insulin Resistance Market are availability of limited drugs and lack of information on insulin resistance. 

Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the insulin resistance market. In 2019, Insulin Resistance Market   share is consolidated by the top ten players present in the market. Insulin resistance, top 10 companies are GlaxoSmithKline Plc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Nova Nordisk, Teva Pharmaceuticals, Sanofi, GlaxoSmithKline, Mylan, Oramed Pharmaceuticals and Takeda Pharmaceuticals.